[5-bromo-1-(3-methyl-butyl)-1H-benzoimidazol-2-yl]-methanol | 554457-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: [5-bromo-1-(3-methyl-butyl)-1H-benzoimidazol-2-yl]-methanol
• 英文别名: [5-bromo-1-(3-methylbutyl)benzimidazol-2-yl]methanol
• CAS: 554457-43-1
• 化学式: C₁₃H₁₇BrN₂O
• 分子量: 297.195
• InChiKey: OOJNZPPLJAFQGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [5-bromo-1-(3-methyl-butyl)-1H-benzoimidazol-2-yl]-methanol 在 氯化亚砜 作用下， 生成 1-[5-bromo-1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-3-isopropyl-1,3-dihydro-benzoimidazol-2-one
  参考文献：
  名称：

  Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity

  摘要：

  Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivatives led to the identification of BMS-433771 (3) as an orally active RSV fusion inhibitor. In order to extend the structure-activity relationships for this compound series, substitution of the benzimidazole ring was examined with a view to establishing additional productive interactions between the inhibitor and functionality present in the proposed binding pocket. Amongst the compounds synthesized, the 5-aminomethyl analogue 10aa demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to BMS-433771 (3), data consistent with an additional productive interaction between the inhibitor and the fusion protein target. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.102
• 作为产物：
  描述：

  异戊胺 在 palladium on activated charcoal 氢气 、 三溴化硼 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 [5-bromo-1-(3-methyl-butyl)-1H-benzoimidazol-2-yl]-methanol
  参考文献：
  名称：

  Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity

  摘要：

  Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivatives led to the identification of BMS-433771 (3) as an orally active RSV fusion inhibitor. In order to extend the structure-activity relationships for this compound series, substitution of the benzimidazole ring was examined with a view to establishing additional productive interactions between the inhibitor and functionality present in the proposed binding pocket. Amongst the compounds synthesized, the 5-aminomethyl analogue 10aa demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to BMS-433771 (3), data consistent with an additional productive interaction between the inhibitor and the fusion protein target. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.102

文献信息

• Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
  申请人：——

  公开号：US20030207868A1

  公开（公告）日：2003-11-06

  The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.

  本发明涉及抗病毒化合物，其制备方法及其组合物，以及在治疗病毒感染中的应用。更具体地，该发明提供了用于治疗呼吸道合胞病毒感染的杂环取代2-甲基苯并咪唑衍生物。
• SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1461035A2

  公开（公告）日：2004-09-29
• EP1461035A4
  申请人：——

  公开号：EP1461035A4

  公开（公告）日：2005-04-06
• US6919331B2
  申请人：——

  公开号：US6919331B2

  公开（公告）日：2005-07-19
• [EN] SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS<br/>[FR] 2-METHYL-BENZIMIDAZOLE SUBSTITUES EN TANT QU'AGENTS ANTIVIRAUX DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003053344A2

  公开（公告）日：2003-07-03

  The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.